Advancing Heart Valve Replacement: Risk Mitigation of Decellularized Pulmonary Valve Preparation for Its Implementation in Public Tissue Banks

The studies performed and reviewed bibliography were able to significantly reduce the original level of risk associated with the clinical application of this homograft's preparation. However, additional in vivo studies and tissue stability tests are still necessary to address the remaining risks associated with reagents' effect on extracellular matrix and storage conditions, which could influence implant failure, before the clinical evaluation procedures can be implemented to determine the efficacy and safety of the new decellularized heart valves.

Authors

Institutions

Publication Details

Journal
Therapeutics and Clinical Risk Management
Published
2025-02-01
DOI
https://doi.org/10.2147/tcrm.s486508
Citations
2
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advancing Heart Valve Replacement: Risk Mitigation of Decellularized Pulmonary Valve Preparation for Its Implementation in Public Tissue Banks

Maria Luisa Pérez, Anna Vilarrodona, María Eugenia Fernández‐Santos, Antonio Ocampo et al.
2 citations
Therapeutics and Clinical Risk Management
Cardiac Valve Diseases and Treatments
2.78
article

Advancing Heart Valve Replacement: Risk Mitigation of Decellularized Pulmonary Valve Preparation for Its Implementation in Public Tissue Banks

Maria Luisa Pérez, Anna Vilarrodona, María Eugenia Fernández‐Santos, Antonio Ocampo, Diletta Trojan, Giulia Montagner, Ramadan Jashari, Elba Agustí, Jose Ignacio Rodríguez Martínez, Ana Rita Piteira, Jaime Tabera, Pablo Martínez‐Legazpi, Cristina Castells‐Sala, Javier Bermejo
article en
2 citations

Abstract

The studies performed and reviewed bibliography were able to significantly reduce the original level of risk associated with the clinical application of this homograft's preparation. However, additional in vivo studies and tissue stability tests are still necessary to address the remaining risks associated with reagents' effect on extracellular matrix and storage conditions, which could influence implant failure, before the clinical evaluation procedures can be implemented to determine the efficacy and safety of the new decellularized heart valves.

Therapeutics and Clinical Risk ManagementVol. Volume 21
Universidad Complutense de Madrid (ES), Cliniques Universitaires Saint-Luc (BE), Universidad Nacional de Educación a Distancia (ES), Instituto de Salud Carlos III (ES), Hospital General Universitario Gregorio Marañón (ES), Vall d'Hebron Institut de Recerca (ES), Veneto Eye Bank Foundation (IT), Biomedical Research Institute (US), Banc de Sang i Teixits (ES)
Openalex Percentile: Top 11%
Cardiac Valve Diseases and Treatments
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.